A phase I study of tipifarnib combined with conventional induction and consolidation therapy for previously untreated patients with acute myeloid leukemia aged 60 years and over-Reference-Cited by-同舟云学术

A phase I study of tipifarnib combined with conventional induction and consolidation therapy for previously untreated patients with acute myeloid leukemia aged 60 years and over

Published:2008-12-18 Issue:4 Volume:23 Page:631-634
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Brandwein J M, ,Leber B F,Howson-Jan K,Schimmer A D,Schuh A C,Gupta V,Yee K W L,Wright J,Moore M,MacAlpine K,Minden M D

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

http://www.nature.com/articles/leu2008341.pdf

Reference16 articles.

1. Baudard M, Marie JP, Cadiou M, Vigui F, Zittoun R . Acute myelogenous leukemia in the elderly: retrospective study of 235 consecutive patients. Br J Haematol 1994; 86: 82–91.

2. Rowe JM, Neuberg D, Friedenberg W, Bennett JM, Paietta E, Makary AZ et al. A phase 3 study of three induction regimens and of priming with GM-CSF in older adults with acute myeloid leukemia: a trial by the Eastern Cooperative Oncology Group. Blood 2004; 103: 479–485.

3. Godwin JE, Kopecky KJ, Head DR, Willman CL, Leith CP, Hynes HE et al. A double-blind placebo-controlled trial of granulocyte colony-stimulating factor in elderly patients with previously untreated acute myeloid leukemia: a Southwest oncology group study (9031). Blood 1998; 91: 3607–3615.

4. Goldstone AH, Burnett AK, Wheatley K, Smith AG, Hutchinson RM, Clark RE . Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trial. Blood 2001; 98: 1302–1311.

5. Grimwade D, Walker H, Harrison G, Oliver F, Chatters S, Harrison CJ et al. The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. Blood 2001; 98: 1312–1320.

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A phase I clinical trial to study the safety of treatment with tipifarnib combined with bortezomib in patients with advanced stages of myelodysplastic syndrome and oligoblastic acute myeloid leukemia;Leukemia Research;2021-06

2. miR-126 Regulates Distinct Self-Renewal Outcomes in Normal and Malignant Hematopoietic Stem Cells;Cancer Cell;2016-02

3. Small molecule inhibitors in acute myeloid leukemia: from the bench to the clinic;Expert Review of Hematology;2014-07-15

4. Novel Targeted Therapeutics for Acute Myeloid Leukemia;Hematologic Cancers: From Molecular Pathobiology to Targeted Therapeutics;2012

5. Multi-institutional phase 2 study of the farnesyltransferase inhibitor tipifarnib (R115777) in patients with relapsed and refractory lymphomas;Blood;2011-11-03